Qiagen N.V. stock (NL0012169213): Q1 2026 results and guidance trimmed

Qiagen N.V. reported Q1 2026 net sales of $492 million and trimmed its 2026 growth outlook, while the stock trades near a 12?month low on the NYSE.

Qiagen N.V. has reported first?quarter 2026 results that came in line with its pre?announcement, with net sales of $492 million and adjusted earnings per share of $0.54, matching consensus expectations. At the same time, the company has trimmed its full?year 2026 guidance, now expecting net sales growth of about 1–2% at constant exchange rates and adjusted EPS of at least $2.43, reflecting weaker demand in key franchises such as QuantiFERON and broader macro headwinds. The stock has been under pressure, trading near a 12?month low on the NYSE under the ticker QGEN, after a roughly 30% decline from the start of the year.

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Qiagen N.V.
• Sector/industry: Life sciences and diagnostics
• Headquarters/country: Netherlands
• Core markets: Molecular diagnostics, sample preparation, and life?science research
• Key revenue drivers: QuantiFERON, sample?preparation kits, and companion diagnostics
• Home exchange/listing venue: NYSE (ticker: QGEN)
• Trading currency: USD

Qiagen N.V.: core business model

Qiagen N.V. operates as a global provider of sample? and assay?technologies for molecular diagnostics, applied testing, and life?science research. The company supplies instruments, reagents, and software that enable laboratories to isolate, purify, and analyze DNA, RNA, and proteins from a wide range of biological samples. Its products are used in clinical diagnostics, pharmaceutical and biotech R&D, academic research, and applied?testing segments such as forensics and food safety.

Qiagen’s business model is built on recurring revenue from consumables and reagents, which typically generate higher margins than instruments. The company also earns revenue from service contracts, software licenses, and companion?diagnostic partnerships with pharmaceutical firms. Its global footprint spans North America, Europe, and Asia?Pacific, with a strong presence in the United States, where many of its diagnostic and research customers are located.

Main revenue and product drivers for Qiagen N.V.

Key revenue drivers for Qiagen include its QuantiFERON franchise, which is used for tuberculosis testing, as well as its sample?preparation platforms and molecular?diagnostics assays. In Q1 2026, net sales rose 2% on a reported basis to $492 million, but declined 1% at constant exchange rates versus the prior?year quarter, indicating that foreign?exchange effects masked underlying softness in demand. The company highlighted that QuantiFERON and certain other franchises faced headwinds, contributing to the decision to lower its full?year 2026 growth targets.

Despite the softer outlook, Qiagen continues to emphasize innovation in areas such as oncology, infectious diseases, and companion diagnostics. The company’s pipeline includes new assays and workflow solutions aimed at high?growth segments like liquid biopsy and next?generation sequencing, which could support longer?term revenue diversification. For US investors, exposure to the US healthcare and life?science markets remains a central element of Qiagen’s investment case, given the size and innovation intensity of these sectors.

Conclusion

Qiagen N.V. has delivered Q1 2026 results that met consensus expectations on earnings per share, but has tempered its full?year outlook amid weaker demand in certain franchises and macroeconomic challenges. The stock now trades near a 12?month low on the NYSE, reflecting investor concerns about growth and margin pressure. For US investors, Qiagen offers exposure to the global life?sciences and diagnostics markets, but the recent guidance cut and valuation multiple suggest that the shares may remain sensitive to execution and macro conditions in the near term. This article does not constitute investment advice. Stocks are volatile financial instruments.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.